- Lilly reports second-quarter 2025 financial results and raises guidance Eli Lilly and Company
- Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar CNBC
- Eli Lilly beats earnings for second quarter on strong GLP-1 sales, but stock dives on GLP-1 pill trial results Yahoo Finance
- Eli Lilly Stock Dives on Weight-Loss Pill Data. Earnings, Zepbound Sales Beat. Barron’s
- Prediction: This Unstoppable Growth Stock Will Be Worth $2 Trillion in the Next 7 Years The Motley Fool
Credit: Source link
























